@RNA_Biotech

Stocks - Biotech - RNAi, mRNA, RNA tech, gene therapy, CRISPR - opinions, news, trading. Top Pick for 2026 $MDNAF $MDNA (.to)

Joined November 2013
  • Tweets3.7K
  • Following124
  • Followers2.4K
179Media
$MDNAF $MDNA.TO
Medicenna Therapeutics
@Medicenna115h
One target. Two pathways. #MDNA209, our potential first-in-class CD122 superantagonist, is designed to inhibit IL-2 and IL-15. New preclinical data in Paris at The Promises of Treg and Interleukin-2 Therapies. Fri, Oct 23 | 4:30 p.m. CEST ir.medicenna.com/news-releas… $MDNAF
Medicenna graphic for an upcoming presentation at The Promises of Treg and Interleukin-2 Therapies conference in Paris, France. Headline: "One Target. Two Pathways." Text: "MDNA209 is designed to block CD122 and inhibit IL-2 and IL-15." Friday, October 23, 4:30 p.m. CEST, presented by Dr. Minh D. To. TSX: MDNA | OTCQB: MDNAF. A 3D render of purple protein clusters fills the right side.

ALT Medicenna graphic for an upcoming presentation at The Promises of Treg and Interleukin-2 Therapies conference in Paris, France. Headline: "One Target. Two Pathways." Text: "MDNA209 is designed to block CD122 and inhibit IL-2 and IL-15." Friday, October 23, 4:30 p.m. CEST, presented by Dr. Minh D. To. TSX: MDNA | OTCQB: MDNAF. A 3D render of purple protein clusters fills the right side.

3
156
RNA_Biotech retweeted
Joe
@GantosjOct 5
$MDNAF $MDNA.TO Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026 ir.medicenna.com/news-releas…

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11...

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers Selected as one...

ir.medicenna.com
3
1
22
2,049
$MRK $MRNA $MDNAF $MDNA.to
GypsyNoLonger | PRISM-11
@GypsyNoLongerAug 20
$MDNAF / $MDNA.TO / $XBI Two pieces, one through-line: Moderna/Merck showed oncology can teach the immune system what to attack. The follow-up asks the next question: can that trained response be preserved, replenished and redeployed? Cullinan, Shimizu, Novartis—and now Medicenna’s clinical framing—make that continuity question increasingly hard to ignore. And that is where MDNA11 gets more interesting, not less. Yesterday’s Instant Analysis: davidbakke.substack.com/p/in… Today’s follow-up: davidbakke.substack.com/p/th…
6
1,772
Medicenna Therapeutics Fiscal Year 2026 Financial Results and Operational Highlights $MDNAF $MDNA (.to) ir.medicenna.com/news-releas…

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights -...

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer...

ir.medicenna.com
4
718
Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms $MDNA (.to) $MDNAF ir.medicenna.com/news-releas…

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2,...

New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio...

ir.medicenna.com
4
8
945
$MDNA $MDNAF
Joe
@GantosjMay 22
Interesting to see $MDNAF $MDNA.to secure the largest portion of the financing; a solid $8M coming from the U.K. investment fund "Sorbie Bornholm". According to the prospectus, the company plans to issue a minimum of 6M Units and up to 10M Units at $0.50 per Unit, for total gross proceeds between $3M and $5M A strong structure that reinforces confidence in the financing strategy and the MDNA11 development path. ir.medicenna.com/news-releas…

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet - Medicenna...

Base shelf prospectus is accessible on SEDAR+ NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medice...

ir.medicenna.com
1
7
1,207
$MDNA $MDNAF Public Offering of Securities $0.50 and one half of one warrant $0.65 ir.medicenna.com/news-releas…

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities - Medicenna...

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics...

ir.medicenna.com
2
4
896
$MDNAF $MDNA
Medicenna Therapeutics
@Medicenna1May 13
Why is MDNA11 being evaluated at the “neoajuvant” setting for Melanoma? It’s about timing. Dosing the first patient in our NEO-CYT trial at up to 12 centers in Italy marks a strategic shift toward potentially curative care. 🧵 (1/4) $MDNA.TO $MDNAF
A title slide featuring the Medicenna and Fondazione Melanoma Onlus logos. The main headline reads "The Science of Timing" with a sub-headline "Why we are moving MDNA11 to the front lines of Melanoma care".

ALT A title slide featuring the Medicenna and Fondazione Melanoma Onlus logos. The main headline reads "The Science of Timing" with a sub-headline "Why we are moving MDNA11 to the front lines of Melanoma care".

5
1,515
Very important progress with MDNA11 $MDNAF $MDNA.TO
Medicenna Therapeutics
@Medicenna1May 12
$MDNAF $MDNA.TO Big news from Medicenna: The first patient has been dosed in the Phase 1b NEO-CYT study! This randomized, multi-centre trial evaluates MDNA11 + nivolumab (± ipilimumab) at up to 12 centers in Italy.
https://ir.medicenna.com/news-releases/news-release-details/medicenna-and-fondazione-melanoma-onlus-announce-first-patient

ALT https://ir.medicenna.com/news-releases/news-release-details/medicenna-and-fondazione-melanoma-onlus-announce-first-patient

3
7
674
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026 $MDNAF $MDNA ir.medicenna.com/news-releas…
1
5
699
Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 MDNA113 vs anti-PD-1 x IL-2α demonstrates superior tolerability, significantly wider therapeutic window $MDNAF $MDNA ir.medicenna.com/news-releas…

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its...

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head...

ir.medicenna.com
1
1
6
834
$MDNAF $MDNA.TO $XBI They have the Map. They have the Machine. They have the Workarounds. What they don’t have is the one layer that decides whether any of it actually works. Tomorrow: first real look at MDNA113 — the conditionally activated bispecific designed to execute without recreating the failure mode. open.substack.com/pub/davidb…
1
9
414
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer $MDNA $MDNAF ir.medicenna.com/news-releas…

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer - Medicenna Therape...

TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the...

ir.medicenna.com
Medicenna Therapeutics
@Medicenna1Apr 9
We are pleased to welcome Dr. Nageatte Ibrahim as Chief Medical Officer (fractional) at Medicenna. With >20 years of oncology experience, her leadership will be pivotal as we advance our immunotherapy pipeline. $MDNAF $MDNA.TO
Corporate announcement graphic from Medicenna featuring a smiling headshot of Dr. Nageatte Ibrahim set against a deep purple, scientific cellular background. Bold white text reads: 'Dr. Nageatte Ibrahim, Appointed Chief Medical Officer.' The Medicenna logo sits in the top left corner, and the company's stock tickers, TSX: MDNA | OTCQX: MDNAF, are displayed in the bottom right

ALT Corporate announcement graphic from Medicenna featuring a smiling headshot of Dr. Nageatte Ibrahim set against a deep purple, scientific cellular background. Bold white text reads: 'Dr. Nageatte Ibrahim, Appointed Chief Medical Officer.' The Medicenna logo sits in the top left corner, and the company's stock tickers, TSX: MDNA | OTCQX: MDNAF, are displayed in the bottom right

1
8
1,269
As we prep to share our latest #MDNA113 data at #AACR26, the #ImmunoOncology space is officially heating up! There is a MASSIVE push in pharma for PD-1 bispecifics. We're seeing >$43 BILLION in recent combined transaction value in this space alone. $MDNAF $MDNA.TO
A text graphic with a dark cellular background. The text reads: Momentum in Immuno-Oncology. Strategic Signals in PD-1 Bispecifics. Greater than $43 Billion in recent combined transaction value." The Medicenna logo and #AACR26 hashtag are in the bottom corners.

ALT A text graphic with a dark cellular background. The text reads: Momentum in Immuno-Oncology. Strategic Signals in PD-1 Bispecifics. Greater than $43 Billion in recent combined transaction value." The Medicenna logo and #AACR26 hashtag are in the bottom corners.

2
6
10
660
$mdna $mdnaf
Medicenna Therapeutics
@Medicenna1Mar 19
Unlocking immunologically "cold" tumors is one of oncology's greatest challenges. We are thrilled to announce that Medicenna will present highly anticipated preclinical data for our first-in-class IL-2-PD-1 Superkine, #MDNA113, at #AACR26 in San Diego! Read the full PR here: ir.medicenna.com/news-releas… $MDNAF $MDNA.TO #Biotech #Oncology #Immunotherapy #CancerResearch (Disclaimer: MDNA113 is investigational. Post contains forward-looking statements. See SEDAR/SEC filings for risks).
2
7
2,017
RNA_Biotech retweeted
Joe
@GantosjMar 18
$MDNAF $MDNA.to to present MDNA-113 at #AACR26 04/21/2026 Notably, immunodynamic and safety data from non-human primate studies will highlight the differentiated profile of MDNA113 ir.medicenna.com/news-releas…

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally...

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor microenvi...

ir.medicenna.com
dough
@semodoughMar 18
$MDNAF Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 - Medicenna Therapeutics ir.medicenna.com/news-releas…

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally...

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor microenvi...

ir.medicenna.com
1
4
18
2,186
$MDNAF is showing serious strength. 📈 • Up 27% from recent lows • Reclaimed the 20-Day MA✅ • Cleared the 50-Day MA ✅ • Eyes on the 200-Day MA next 🎯 $MDNA $XBI #Biotech #StockMarket
2
5
1,294
$MDNA $MDNAF 7th Annual Glioblastoma Summit: February 19 BIO Investment and Growth Summit : March 2-3 38th Annual ROTH Conference: March 22-24 BIO-Europe Spring Conference: March 23-25
Medicenna Therapeutics
@Medicenna1Feb 18
$MDNAF $MDNA.TO Medicenna is hitting the road! Today we announced our Spring 2026 conference lineup. Kicking off TOMORROW in Boston: CEO Dr. Fahar Merchant presents clinical updates on bizaxofusp in recurrent #Glioblastoma at the 7th Annual GBM Summit. 🔗 PR:ir.medicenna.com/news-releas… 🧵 1/2
A graphic with a deep purple background featuring the Medicenna logo and tickers TSX: MDNA and OTCQX: MDNAF at the top. The main text reads "Spring 2026 Conference Roadmap." On the right side is a detailed 3D illustration of a purple molecular structure. Small text at the bottom reads "Swipe to see upcoming events

ALT A graphic with a deep purple background featuring the Medicenna logo and tickers TSX: MDNA and OTCQX: MDNAF at the top. The main text reads "Spring 2026 Conference Roadmap." On the right side is a detailed 3D illustration of a purple molecular structure. Small text at the bottom reads "Swipe to see upcoming events

A presentation slide with a purple background detailing the 7th Annual Glioblastoma Development Summit. Date: February 19, 2026, in Boston, MA. Format: Presentation and Panel Discussions at 10:00 AM EST. Presenter: Dr. Fahar Merchant, President and CEO. The presentation topic is "Surmounting Barriers in Non-resectable Recurrent Glioblastoma with Bizaxofusp.

ALT A presentation slide with a purple background detailing the 7th Annual Glioblastoma Development Summit. Date: February 19, 2026, in Boston, MA. Format: Presentation and Panel Discussions at 10:00 AM EST. Presenter: Dr. Fahar Merchant, President and CEO. The presentation topic is "Surmounting Barriers in Non-resectable Recurrent Glioblastoma with Bizaxofusp.

2
7
964
Medicenna Third Quarter Fiscal 2026 ABILITY-1 new expansion cohort NSCLC and colorectal cancer (mono- and combination in TMB-H and MSI-H cohorts) (both have blockbuster market opportunities) $MDNA $MDNAF ir.medicenna.com/news-releas…

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate...

Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated...

ir.medicenna.com
1
8
782
$MDNAF $MDNA great work by David: PRISM-11 external scientific-intelligence and interpretive framework now used by the company substack.com/home/post/p-186…
1
3
7
1,216
Load more